What’s new, what’s next and where to find us. This is your hub for our CRO lab announcements, insights and events—because in bioanalysis, momentum matters.
Learn how Veloxity Labs supported Toralgen's breakthrough oral biologics platform with advanced LC-MS/MS bioanalysis, method development and pharmacokinetic expertise.
Veloxity Labs, a leading bioanalytical CRO specializing in LC-MS bioanalysis, today announced strong first quarter growth and continued expansion in 2026.
Our CEO, Shane Needham, PhD, was recently featured in The Analytical Scientist discussing the impact of GLP-1 receptor agonists and emerging peptide therapeutics.
Veloxity Labs has acquired the SCIEX ZenoTOF 8600 system, becoming the first bioanalytical CRO to bring this accurate-mass system online. The 8600 adds HRAM selectivity/sensitivity and expanded mass range for intact peptides/proteins—speeding method cycles for GLP-1 RAs and broader peptide programs while complementing our triple-quads. Delivery is expected this year; install/qualification begins January 2026.
Read the full release.
We’ve partnered with Carolina Martinez — a record-setting sprinter, Bradley University standout and cancer survivor — in a powerful new NIL collaboration.
We’re proud to support Silo Pharma in advancing SPC-15, a novel intranasal therapy for PTSD. We're providing GLP bioanalysis for their IND-enabling safety study.
Veloxity Labs is proud to participate in the 2026 St. Jude Metamora to Peoria Run, continuing a tradition that reflects our commitment to improving lives.
Veloxity Labs will attend the PBSS Boston IND Filing and Nonclinical Considerations for Emerging Modalities on September 9 in Cambridge, Massachusetts.
Veloxity Labs is a proud sponsor of the 2026 Animal Health Summit one of the leading global gatherings focused on innovation across the animal health industry.
